KR20240024842A - Nlrp3 억제제의 제조 공정 - Google Patents

Nlrp3 억제제의 제조 공정 Download PDF

Info

Publication number
KR20240024842A
KR20240024842A KR1020237044161A KR20237044161A KR20240024842A KR 20240024842 A KR20240024842 A KR 20240024842A KR 1020237044161 A KR1020237044161 A KR 1020237044161A KR 20237044161 A KR20237044161 A KR 20237044161A KR 20240024842 A KR20240024842 A KR 20240024842A
Authority
KR
South Korea
Prior art keywords
piperidine
group
typically
solvent
protected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237044161A
Other languages
English (en)
Korean (ko)
Inventor
폴 프레이저
제타 팔구나
말레쉬 바라타
조세피네 엘리트 프랑수아즈 신큐알브레
레지스 장 조르지스 몬디레
파올로 토사티
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20240024842A publication Critical patent/KR20240024842A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237044161A 2021-06-23 2022-06-23 Nlrp3 억제제의 제조 공정 Pending KR20240024842A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202141028180 2021-06-23
IN202141028180 2021-06-23
PCT/EP2022/067126 WO2022268935A2 (en) 2021-06-23 2022-06-23 Novel process

Publications (1)

Publication Number Publication Date
KR20240024842A true KR20240024842A (ko) 2024-02-26

Family

ID=82458485

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044161A Pending KR20240024842A (ko) 2021-06-23 2022-06-23 Nlrp3 억제제의 제조 공정

Country Status (12)

Country Link
US (1) US20240150291A1 (https=)
EP (1) EP4359385A2 (https=)
JP (1) JP2024524215A (https=)
KR (1) KR20240024842A (https=)
CN (1) CN118019727A (https=)
AR (1) AR126215A1 (https=)
AU (1) AU2022300325A1 (https=)
CA (1) CA3219597A1 (https=)
IL (1) IL308071A (https=)
MX (1) MX2023014547A (https=)
TW (1) TW202317514A (https=)
WO (1) WO2022268935A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128498A1 (es) * 2022-02-15 2024-05-15 Hoffmann La Roche Procesos novedosos
WO2024133610A1 (en) * 2022-12-23 2024-06-27 F. Hoffmann-La Roche Ag Proccesses for the preparation of an nlrp3 inhibitor
IL325043A (en) 2023-08-16 2026-01-01 Hoffmann La Roche Process for the preparation of 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indecen-4-yl)carbamoyl)piperidine-4-sulfonamide
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69727837T2 (de) * 1997-05-02 2004-12-30 Dr. Reddy's Research Foundation, Hyderabad Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
HUP0303204A3 (en) * 2000-11-16 2010-04-28 Sankyo Co 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
US7220735B2 (en) * 2002-04-18 2007-05-22 Schering Corporation Benzimidazolone histamine H3 antagonists
TW200524865A (en) * 2003-10-08 2005-08-01 Nicholas Piramal India Ltd Fibrinogen receptor antagonists and their use
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
JP5508027B2 (ja) * 2007-02-22 2014-05-28 メルク セローノ ソシエテ アノニム キノキサリン化合物及びその使用
JP5898962B2 (ja) * 2012-01-11 2016-04-06 東京応化工業株式会社 レジスト組成物及びレジストパターン形成方法
WO2017095758A1 (en) * 2015-12-01 2017-06-08 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use
US11465992B2 (en) * 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
EP3668861A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3773576A4 (en) * 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CR20200588A (es) * 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
CA3113573A1 (en) * 2018-09-21 2020-03-26 Novartis Ag Isoxazole carboxamide compounds and uses thereof
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020157069A1 (en) * 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
WO2022268935A3 (en) 2023-02-02
IL308071A (en) 2023-12-01
TW202317514A (zh) 2023-05-01
EP4359385A2 (en) 2024-05-01
US20240150291A1 (en) 2024-05-09
CN118019727A (zh) 2024-05-10
AR126215A1 (es) 2023-09-27
AU2022300325A8 (en) 2023-11-16
AU2022300325A1 (en) 2023-11-02
WO2022268935A2 (en) 2022-12-29
CA3219597A1 (en) 2022-12-29
JP2024524215A (ja) 2024-07-05
MX2023014547A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
KR20240024842A (ko) Nlrp3 억제제의 제조 공정
EP3099685B1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
EA034169B1 (ru) Синтез полициклических карбамоилпиридоновых соединений
AU2021258083A1 (en) Process for the preparation of 3-substituted 5-amino-6-H-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
CN102203062A (zh) 用于合成8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮化合物的方法和中间体
US20240400516A1 (en) Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivataives
EP4638422A1 (en) Proccesses for the preparation of an nlrp3 inhibitor
JP2022532875A (ja) Cracチャネル阻害剤の合成
HK40105889A (zh) 用於制备nlrp3抑制剂的方法
ES2912409T3 (es) Intermedios y procesos para la preparación de linagliptina y sus sales
JP2016172755A (ja) 抗ウイルス化合物およびその有用な中間体の調製方法
CN118234729A (zh) 用于制备双环甘氨酸-脯氨酸化合物和其单环甘氨酸-脯氨酸中间体的方法
TW202608878A (zh) Nlrp3炎症小體抑制劑及其用途
HK40012866A (en) Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
HK40012866B (en) Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
IL325043A (en) Process for the preparation of 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indecen-4-yl)carbamoyl)piperidine-4-sulfonamide
CA2999199A1 (en) Crosslinked nucleic acid guna, method for producing same, and intermediate compound
HK1217493A1 (zh) 製備抗病毒組合物的方法及其中間體的應用
CN102464691A (zh) 制备抗病毒组合物的方法及其中间体的应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250609

Comment text: Request for Examination of Application